ABSTRACT
Objectives
Whether depression affects activities of daily living (ADLs) in patients with Parkinson’s disease (PD) via excessive daytime sleepiness (EDS) remains unclear; moreover, few longitudinal studies have been conducted.
Methods
We recruited 421 patients from the Parkinson’s Progression Markers Initiative. We constructed a latent growth mediation model to explore the longitudinal mediating effect of depression on the relationship between EDS and ADLs.
Results
EDS (p < .001) and depression scores (p < .001) both increased, and ADL scores (p < .001) decreased. Moreover, EDS was positively correlated with depression, whereas an increase in EDS significantly reduced ADLs. The initial value (95% confidence interval [CI]: 0.026, 0.154) and the rate of change (95% CI: 0.138, 0.514) of self-reported depression measured using the Geriatric Depression Scale(GDS) partially mediated the association between EDS and ADL score.
Conclusions
The indirect effect of the longitudinal changes of depression on the relationship between EDS and ADLs highlights the importance of depression changes in PD patients with EDS.
Clinical Implications
Depression should be considered a mediator by clinicians; preventing the worsening of depression is essential for improving ADLs in patients with PD, especially those with EDS.
Clinical implications
●The significant association between depression and ADLs in people with PD highlights the importance of preventing depression.
●The non-significant correlation between the progression of depression and baseline depression symptoms suggests that it is essential to note changes in depression during the disease course, especially in PD patients without depression at baseline who exhibit changes in mood and EDS.
●The mediating effect of depression on the association between EDS and ADLs may be valuable for developing interventions to help patients with EDS improve their basic abilities.
Acknowledgments
All authors are grateful to the participants for their support and cooperation in making this research possible. We also thank the reviewers for their constructive ideas, and Sarina Iwabuchi, PhD, from Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing the language of a draft of this manuscript.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
These data were derived from the following resources available in the public domain:[Parkinson’s Progression Markers Initiative (PPMI), URLs: www.ppmi-info.org]